Anonymous
Guest
Anonymous
Guest
On the flip side, if the new reps are good at what they do, they can help increase the price Amarin eventually gets from Big Pharma. If the buyout doesn't occur until end of 2013 (after Anchor is FDA approved), the reps might be able to make serious $, especially if Amarin gives them stock options.